CERO
Price
$1.42
Change
-$0.05 (-3.40%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
4.3M
LSB
Price
$2.10
Change
-$0.07 (-3.23%)
Updated
Mar 10, 04:44 PM (EDT)
Capitalization
40.07M
Ad is loading...

CERO vs LSB

Header iconCERO vs LSB Comparison
Open Charts CERO vs LSBBanner chart's image
CERo Therapeutics Holdings
Price$1.42
Change-$0.05 (-3.40%)
Volume$412
Capitalization4.3M
LakeShore Biopharma
Price$2.10
Change-$0.07 (-3.23%)
Volume$159
Capitalization40.07M
CERO vs LSB Comparison Chart
Loading...
CERO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERO vs. LSB commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERO is a Hold and LSB is a Buy.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (CERO: $1.44 vs. LSB: $2.04)
Brand notoriety: CERO and LSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CERO: 18% vs. LSB: 15%
Market capitalization -- CERO: $4.3M vs. LSB: $40.07M
CERO [@Biotechnology] is valued at $4.3M. LSB’s [@Biotechnology] market capitalization is $40.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.07B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERO’s FA Score shows that 1 FA rating(s) are green whileLSB’s FA Score has 1 green FA rating(s).

  • CERO’s FA Score: 1 green, 4 red.
  • LSB’s FA Score: 1 green, 4 red.
According to our system of comparison, both CERO and LSB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERO’s TA Score shows that 4 TA indicator(s) are bullish while LSB’s TA Score has 2 bullish TA indicator(s).

  • CERO’s TA Score: 4 bullish, 3 bearish.
  • LSB’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, CERO is a better buy in the short-term than LSB.

Price Growth

CERO (@Biotechnology) experienced а -8.01% price change this week, while LSB (@Biotechnology) price change was -10.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.83%. For the same industry, the average monthly price growth was -7.68%, and the average quarterly price growth was -7.34%.

Reported Earning Dates

CERO is expected to report earnings on Mar 24, 2023.

Industries' Descriptions

@Biotechnology (+0.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LSB($40.1M) has a higher market cap than CERO($4.3M). LSB YTD gains are higher at: -41.043 vs. CERO (-76.082). LSB has more cash in the bank: 49.5M vs. CERO (3.38M). CERO has less debt than LSB: CERO (1.81M) vs LSB (369M).
CEROLSBCERO / LSB
Capitalization4.3M40.1M11%
EBITDAN/A-220.1M-
Gain YTD-76.082-41.043185%
P/E RatioN/AN/A-
RevenueN/A672M-
Total Cash3.38M49.5M7%
Total Debt1.81M369M0%
TECHNICAL ANALYSIS
Technical Analysis
CEROLSB
RSI
ODDS (%)
Bullish Trend 7 days ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 7 days ago
43%
Bullish Trend 7 days ago
83%
Momentum
ODDS (%)
Bearish Trend 7 days ago
35%
Bearish Trend 7 days ago
51%
MACD
ODDS (%)
N/A
Bearish Trend 7 days ago
49%
TrendWeek
ODDS (%)
Bearish Trend 7 days ago
57%
Bearish Trend 7 days ago
68%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
71%
Bearish Trend 7 days ago
74%
Advances
ODDS (%)
Bullish Trend 11 days ago
50%
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 7 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
62%
Bullish Trend 7 days ago
68%
Aroon
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 7 days ago
88%
View a ticker or compare two or three
Ad is loading...
CERO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X87222.1950001156.515600
+1.34%
Bitcoin cryptocurrency
GME24.30-0.10
-0.41%
GameStop Corp
AAPL235.93-2.10
-0.88%
Apple
SPY576.86-6.91
-1.18%
SPDR® S&P 500® ETF Trust
TSLA272.04-12.61
-4.43%
Tesla

CERO and

Correlation & Price change

A.I.dvisor tells us that CERO and BRTX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CERO and BRTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERO
1D Price
Change %
CERO100%
-0.34%
BRTX - CERO
30%
Poorly correlated
-5.30%
IBIO - CERO
29%
Poorly correlated
-7.18%
KALV - CERO
27%
Poorly correlated
+3.68%
IMRN - CERO
26%
Poorly correlated
-5.84%
JAGX - CERO
23%
Poorly correlated
-1.02%
More

LSB and

Correlation & Price change

A.I.dvisor tells us that LSB and APM have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSB and APM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSB
1D Price
Change %
LSB100%
-2.40%
APM - LSB
26%
Poorly correlated
+1.93%
GLTO - LSB
25%
Poorly correlated
+1.50%
SKYE - LSB
20%
Poorly correlated
+1.99%
CERO - LSB
15%
Poorly correlated
-0.34%
QTTB - LSB
12%
Poorly correlated
N/A
More